TABLE 5.

Treatment-emergent adverse events occurring in at least 10% of subjects overall after single and multiple i.v. doses of eravacycline

Adverse event	No. (%) of subjects in:
	Single-ascending-dose study (n = 42)	Multiple-ascending-dose study (n = 24)
Any event	19 (45.2)	21 (87.5)
Diarrhea	0	4 (12.5)
Headache	3 (5.4)	6 (18.8)
Infusion site discomfort	0	7 (21.9)
Infusion site pain	2 (3.6)	11 (34.4)
Infusion site erythema	1 (1.8)	10 (41.7)
Nausea	8 (14.3)	11 (45.8)
Pain in extremity	2 (3.6)	5 (15.6)
Phlebitis superficial	0	14 (43.8)